Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37b416a8c0d2b0f1c3d6026d932027af |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3231 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
filingDate |
2017-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44e24c90e1ce17413801e48621f96d45 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88be47b8fc939af7a183841dd71eb0e9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ecd26dc154d2cff520cdd3cc5e84f5af |
publicationDate |
2020-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2020325539-A1 |
titleOfInvention |
Cancer biomarkers and methods of use |
abstract |
The present disclosure relates to a method of determining the presence of lung cancer in a subject comprising the steps of detecting an expression level of miR-1246 alone or in combination with an expression level of miR-1290 in a sample obtained from the subject wherein the increase in miR-1246 and/or miR-1290 in the sample obtained from the subject relative to the expression level of miR-1246 or miR-1290 in the control sample indicates the presence of lung cancer in the subject. The disclosure further comprises a method of monitoring a response to therapy in a lung cancer patient, a method of prognosis of lung cancer in a patient and a method for treating lung cancer in a subject comprising the use of inhibitors of miR-1246 and/or miR-1290 alone or in combination. In a specific embodiment, miR-1246 and/or miR-1290 levels are used to predict response to chemotherapy and progression in human non-small cell lung cancer (NSCLC) patients. |
priorityDate |
2016-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |